Brundin Lou, Kobelt Gisela, Berg Jenny, Capsa Daniela, Eriksson Jennifer
Division of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
European Health Economics, Mulhouse, France.
Mult Scler. 2017 Aug;23(2_suppl):179-191. doi: 10.1177/1352458517708682.
To assess the value of management strategies in multiple sclerosis (MS), outcome data have to be combined with cost data. This requires that cost data be regularly updated.
This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity and health-related quality of life (HRQoL). Descriptive analyses are presented by level of severity; costs are estimated in the societal perspective, in 2015 SEK.
A total of 1864 patients (mean age 56 years) participated in Sweden; 74% were below retirement age, and of these, 55% were employed. MS was reported to affect productivity at work in 78% of patients. Overall, 94% and 72% of patients felt that fatigue and cognition were a problem, respectively. The mean utility and costs were 0.757 and 244,000SEK at Expanded Disability Status Scale (EDSS) 0-3, 0.563 and 384,000SEK at EDSS 4-6.5 and 0.202 and 888,000SEK at EDSS 7-9, respectively. The average cost of a relapse was 36,900SEK.
This study illustrates the burden of MS on Swedish patients and provides current data that are important for the development of health policies.
为评估多发性硬化症（MS）管理策略的价值，必须将结果数据与成本数据相结合。这就要求定期更新成本数据。
本研究是一项在16个国家开展的横断面回顾性研究的一部分，收集有关资源消耗、工作能力和健康相关生活质量（HRQoL）的当前数据。按严重程度水平进行描述性分析；从社会角度估算成本，以2015年瑞典克朗计。
瑞典共有1864名患者（平均年龄56岁）参与；74%未到退休年龄，其中55%受雇。据报告，78%的患者MS影响工作效率。总体而言，分别有94%和72%的患者认为疲劳和认知是问题。在扩展残疾状态量表（EDSS）0 - 3级时，平均效用和成本分别为0.757和244,000瑞典克朗；在EDSS 4 - 6.5级时，为0.563和384,000瑞典克朗；在EDSS 7 - 9级时，为0.202和888,000瑞典克朗。复发的平均成本为36,900瑞典克朗。
本研究说明了MS给瑞典患者带来的负担，并提供了对卫生政策制定很重要的当前数据。
